What it's for (Indications)
- Not applicable to this request.
- For clinical information regarding indications for lignocaine (lidocaine), please refer to specific product labeling based on its formulation (e.
- g.
- , topical, injectable, intravenous) and approved therapeutic uses (e.
- g.
- , local anesthesia, antiarrhythmic, neuropathic pain management).
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Not applicable to this request. Dosage for lignocaine (lidocaine) varies significantly based on the route of administration, formulation concentration, indication, patient's age and weight, concomitant medications, and overall clinical status. Precise dosing guidelines must be strictly followed as per national formularies and manufacturer's instructions to ensure efficacy and minimize systemic toxicity. |
Safety & Warnings
Common Side Effects
- Not applicable to this request.
- Systemic side effects of lignocaine (lidocaine) can range from mild (e.
- g.
- , lightheadedness, dizziness, paresthesia, tremors) to severe (e.
- g.
- , seizures, cardiovascular depression, respiratory arrest).
- Local adverse effects can include irritation, erythema, edema, or allergic reactions at the site of application/injection.
- Close monitoring for adverse reactions is crucial during and after administration.
Serious Warnings
- Black Box Warning: Serious warnings have been issued regarding the systemic toxicity of lidocaine, particularly when administered in high doses, applied to large or compromised surface areas, or through accidental ingestion. Systemic absorption of lidocaine can lead to severe central nervous system (CNS) adverse events, which may include lightheadedness, nervousness, dizziness, blurred vision, tremors, somnolence, seizures, and, in severe cases, respiratory depression and arrest. Cardiovascular toxicity is also a significant concern, manifesting as bradycardia, hypotension, myocardial depression, and potentially leading to cardiac arrest. A critical warning exists for accidental ingestion, especially by children, of highly concentrated formulations such as viscous lidocaine 2%, which has resulted in numerous fatalities; this underscores the absolute necessity for careful storage and precise administration to prevent unsupervised access. Healthcare professionals must adhere rigorously to recommended dosing guidelines, monitor patients diligently for any signs of systemic toxicity during and after administration, and ensure meticulous application techniques to mitigate these life-threatening risks. The concomitant use of other local anesthetics or drugs known to prolong lidocaine's half-life should be approached with extreme caution, due to the increased potential for additive systemic effects and enhanced toxicity. This warning emphasizes the critical need for vigilant patient selection, careful dose titration, and continuous clinical monitoring to ensure optimal patient safety and prevent severe adverse outcomes.
- Not applicable to this request.
- General warnings for lignocaine (lidocaine) include caution in patients with hepatic or renal impairment, cardiac disease, epilepsy, and in elderly or debilitated patients.
- Avoid use on compromised skin or large areas when using topical formulations due to increased systemic absorption.
- Strict adherence to proper administration techniques and monitoring for signs of systemic toxicity are paramount.
- Special precautions apply to use in pediatric populations, particularly with oral viscous lidocaine, due to heightened risk of accidental ingestion and systemic toxicity.
- Concurrent use with other local anesthetics or medications affecting cardiac conduction or hepatic metabolism requires careful consideration.
How it Works (Mechanism of Action)
Not applicable to this request. Lignocaine (lidocaine) primarily acts by blocking voltage-gated sodium channels in neuronal cell membranes. This action inhibits the initiation and propagation of nerve impulses, thereby producing local anesthetic effects. As an antiarrhythmic (Class Ib), it stabilizes the neuronal membrane in cardiac tissue, reducing automaticity and shortening the refractory period, particularly in ischemic myocardium, without significantly affecting conduction velocity or prolonging repolarization in healthy cardiac tissue.